To fund its attempts to convey MDMA therapy to market, MAPS Community Reward Corporation (PBC) — MAPS’ pharma subsidiary, which bifurcated in 2014 but didn't take expense in return for fairness and could not safe the $70 million necessary to go forward — has morphed into your for-income Lykos Therapeutics.The newest episode of 'Higher Modern